Dengue vaccine gets a makeover: new formula tested in phase 3 trial

NCT ID NCT07047521

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This phase 3 trial is testing whether a new formulation of Takeda's dengue vaccine (TDV) works as well as the current approved version. About 496 healthy adults aged 18-60 who have never had dengue will receive two shots three months apart. The main goal is to compare immune responses between the two formulations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tetravalent Dengue Vaccine (TDV, also known as TAK-003)
What this could lead to: If successful, this could confirm that the new formulation works as well as the approved vaccine, potentially simplifying manufacturing or distribution.
What could go wrong: This is a non-endemic area study in healthy adults, so results may not fully predict effectiveness in real-world dengue-endemic regions. The trial is also relatively small (496 participants).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DENGUE FEVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dengue disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DENGUE FEVER

Contacts and locations

Locations

Emeritus Research Camberwell (Melbourne)

Camberwell, Victoria, 3124, Australia
Emeritus Research Sydney

Botany, New South Wales, 2019, Australia
Paratus Clinical Research Central Coast

Kanwal, New South Wales, 2259, Australia
Paratus Clinical Research Western Sydney

Blacktown, New South Wales, 2150, Australia
Veritus Research

Bayswater, Victoria, 3153, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.